Impact of atomoxetine on subjective attention and memory difficulties in perimenopausal and postmenopausal women

Menopause

Volumn 18, Issue 5, 2011, Pages 542-548

  Neill Epperson, C ^a,b,c   Pittman, Brian ^b   Czarkowski, Kathryn A ^a   Bradley, Jeanette ^a   Quinlan, Donald M ^b   Brown, Thomas E ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Aging; Atomoxetine; Concentration; Memory; Menopause

Indexed keywords

ATOMOXETINE;

ADULT; ARTICLE; ATTENTION DISTURBANCE; BROWN ATTENTION DEFICIT DISORDER SCALE; CLIMACTERIUM; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; EXECUTIVE FUNCTION; FEMALE; HUMAN; MEMORY DISORDER; MENOPAUSAL SYNDROME; MENTAL CONCENTRATION; NEUROPSYCHOLOGICAL TEST; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RECALL; SELF REPORT; SHORT TERM MEMORY; TREATMENT DURATION; WORKING MEMORY;

ADRENERGIC UPTAKE INHIBITORS; ATTENTION; CROSS-OVER STUDIES; FEMALE; HUMANS; MEMORY DISORDERS; MEMORY, SHORT-TERM; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PERIMENOPAUSE; PILOT PROJECTS; POSTMENOPAUSE; PROPYLAMINES; TREATMENT OUTCOME;

EID: 79959975063     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181fcafd6     Document Type: Article

References (58)

1. Mitchell ES, Woods NF. Midlife women's attributions about perceived memory changes: observations from the Seattle Midlife Women's Health Study. J Womens Health Gend Based Med 2001;10:351-362. (Pubitemid 32976194)
2. Minkin MJ, Wright CV, eds. A Woman's Guide to Menopause and Perimenopause. 1st ed. New Haven, CT: Yale University Press, 2004.
3. Brizendine L, ed. The Female Brain. 1st ed. New York, NY: Broadway, 2006.
4. Fuh JL, Wang SJ, Lee SJ, Lu SR, Juang KD. A longitudinal study of cognition change during early menopausal transition in a rural community. Maturitas 2006;53:447-453.
5. Henderson VW, Guthrie JR, Dudley EC, Burger HG, Dennerstein L. Estrogen exposures and memory at midlife: a population-based study of women. Neurology 2003;60:1369-1371. (Pubitemid 36461000)
6. Luetters C, Huang MH, Seeman T, et al. Menopause transition stage and endogenous estradiol and follicle-stimulating hormone levels are not related to cognitive performance: cross-sectional results from the Study of Women's Health Across the Nation (SWAN). J Womens Health 2007;16:331-344. (Pubitemid 46668914)
7. Halbreich U, Lumley LA, Palter S, Manning C, Gengo F, Joe S. Possible acceleration of age effects on cognition following menopause. J Psychiatr Res 1995;29:153-163.
8. Kok HS, Kuh D, Cooper R, et al. Cognitive function across the life course and the menopausal transition in a British birth cohort. Menopause 2006;13:19-27.
9. Krug R, Born J, Rasch B. A 3-day estrogen treatment improves prefrontal cortex-dependent cognitive function in postmenopausal women. Psychoneuroendocrinology 2006;31:965-975. (Pubitemid 44148914)
10. Stevens MC, Clark VP, Prestwood KM. Low-dose estradiol alters brain activity. Psychiatry Res 2005;139:199-217. (Pubitemid 41116664)
11. Voytko ML, Murray R, Higgs CJ. Executive function and attention are preserved in older surgically menopausal monkeys receiving estrogen or estrogen plus progesterone. J Neurosci 2009;29:10362-10370.
12. Wegesin DJ, Stern Y. Effects of hormone replacement therapy and aging on cognition: evidence for executive dysfunction. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 2007;14:301-328. (Pubitemid 46598784)
13. Arnsten AF. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs 2009;23:33-41.
14. Joffe H, Hall JE, Gruber S, et al. Estrogen therapy selectively enhances prefrontal cognitive processes: a randomized, double-blind, placebocontrolled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women. Menopause 2006;13:411-422.
15. Simpkins JW, Singh M. More than a decade of estrogen neuroprotection. Alzheimer Dement 2008;4:S131-S136.
16. Suzuki S, Brown CM, Wise PM. Mechanisms of neuroprotection by estrogen. Endocrine 2006;29:209-215. (Pubitemid 44097364)
17. Amin Z, Canli T, Epperson CN. Effect of estrogen-serotonin interactions on mood and cognition. Behav Cogn Neurosci Rev 2005;4:43-58. (Pubitemid 41345284)
18. Sherwin BB, Henry JF. Brain aging modulates the neuroprotective effects of estrogen on selective aspects of cognition in women: a critical review. Front Neuroendocrinol 2008;29:88-113.
19. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651-2662. (Pubitemid 37430136)
20. Zandi PP, Carlson MC, Plassman BL. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 2002;288:2123-2129. (Pubitemid 35265379)
21. Sherwin BB, Tulandi T. "Add-back" estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri. J Clin Endocrinol Metab 1996;81:2545-2549. (Pubitemid 26240275)
22. Shifren JL, Schiff I. Role of hormone therapy in the management of menopause. Obstet Gynecol 2010;115:839-855.
23. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002;27:699-711. (Pubitemid 35335888)
24. Gehlert DR, Schober DA, Hemrick-Luecke SK, et al. Novel halogenated analogs of atomoxetine that are potent and selective inhibitors of norepinephrine uptake in brain. Neurochem Int 1995;26:47-52.
25. Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs 2009;11:203-226.
26. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including and assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004;114:e1-e8.
27. Adler LA, Spencer T, Brown TE, et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol 2009;29:44-50.
28. Koda K, Ago Y, Cong Y, Kita Y, Takuma K, Matsuda T. Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. J Neurochem 2010;114:259-270.
29. Spitzer RL, Williams JBW, Gibbon M, First MB. Structured Clinical Interview for DSM-III-R-Non-Patient Edition (SCID-NP, Version 1.0). Washington, DC: American Psychiatric Press, 1990.
30. Orvaschel H, Puig-Antich J. Schedule for Affective Disorder and Schizophrenia for School-Age Children-Epidemiologic, 4th Version. Ft Lauderdale, FL: Nova University Center for Psychological Study, 1987.
31. Seidman LJ, Biederman J, Weber W, et al. Neuropsychological function in adults with attention-deficit hyperactivity disorder. Biol Psychiatry 1998;44:260-268. (Pubitemid 28389711)
32. Brown TE. Brown Attention Deficit Disorders Scale for Adolescents and Adults. Toronto, Ontario, Canada: The Psychological Corporation, 1996.
33. Kooij JS, Boonstra AM, Swinkels SHN, Bekker EM, Nooord I, Buitelaar JK. Reliability, validity and utility of instruments for self-report and informant report concerning symptoms of ADHD in adult patients. J Atten Disord 2008;11:445-458.
34. Spencer TJ, Adler LA, Weisler RH, Youcha SH. Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study. J Clin Psychiatry 2008;69:1437-1448.
35. Brown TE, Quinlan D. Assessing OROS methylphenidate effects on executive functions in adults with ADHD. Paper presented at: Institute on Psychiatric Services Annual Meeting; October 6-10, 2004; Atlanta, GA.
36. Brown TE, Holdnack J, Saylor K, et al. Effect of atomoxetine on executive function impairments in adults with ADHD [e-pub]. J Atten Disord 2009.
37. Wechsler D. Wechsler Adult Intelligence Scale. 3rd ed. San Antonio, TX: The Psychological Corporation, 1997.
38. Wechsler D. Weschler Memory Scale. 3rd ed. San Antonio, TX: The Psychological Corporation, 1997.
39. Hervey AS, Epstein JN, Curry JF. Neuropsychology of adults with attention-deficit/hyperactivity disorder: a meta-analytic review. Neuropsychology 2004;18:485-503. (Pubitemid 38944385)
40. Lokken KL, Ferraro FR. The relationship between menopausal status, phase of menstrual cycle, and replacement estrogen on cognition in healthy women without dementia. J Psychol 2006;140:533-547. (Pubitemid 44846508)
41. Maki PM, Gast MJ, Vieweg AJ, Burriss SW, Yaffe K. Hormone therapy in menopausal women with cognitive complaints: a randomized, doubleblind trial. Neurology 2007;69:1322-1330. (Pubitemid 47482446)
42. Alhola P, Polo-Kantola P, Erkkola R, Portin R. Estrogen therapy and cognition: a 6-year single-blind follow-up study in postmenopausal women. Neurology 2006;67:706-709. (Pubitemid 44273628)
43. Amin Z, Gueorguieva R, Cappiello A, et al. Estradiol and tryptophan depletion interact to modulate cognition in menopausal women. Neuropsychopharmacology 2006;31:2489-2497. (Pubitemid 44607066)
44. Epperson CN, Amin Z, Naftolin F, et al. The resistance to depressive relapse in menopausal women undergoing tryptophan depletion: preliminary findings. J Psychopharmacol 2007;21:414-420. (Pubitemid 47077298)
45. Freeman EW. Associations of depression with the transition to menopause. Menopause 2010;17:823-827.
46. Bierman EJM, Comijs HC, Jonker C, Beekman A. Effects of anxiety versus depression on cognition in later life. Am J Geriatr Psychiatry 2005;13:686-693. (Pubitemid 41197239)
47. Beck AT, Steer RA. Manual for the Beck Depression Inventory. San Antonio, TX: Psychological Corporation, 1993.
48. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56:893-897. (Pubitemid 19008360)
49. McNair ML, Lorr M, Droppleman LF. POMS Manual: Profile of Mood States. San Diego, CA: EdITS, 1981.
50. Brunner E, Domhof S, Langer F. Nonparametric Analysis of Longitudinal Data in Factorial Experiments. New York, NY: John Wiley & Sons, 2002.
51. Brown TE. Executive functions and attention deficit hyperactivity disorder: implications of two conflicting views. Int J Disabil Dev Educ 2006;53:35-46. (Pubitemid 43328825)
52. Biederman J, Petty CR, Fried R. Discordance between psychometric testing and questionnaire-based definitions of executive function deficits in individuals with ADHD. J Atten Disord 2008;12:92-102.
53. Shallice T. Higher-order cognitive impairments and frontal lobe lesions in man. In: Levin HS, ed. Frontal Lobe Function and Dysfunction. New York, NY: Oxford University Press, 1991:125-138.
54. Burgess PW, Rabbit P. Theory and methodology in executive function research. In: Rabbitt P, ed. Methodology of Frontal and Executive Function. East Sussex, UK: Psychology Press Publishers, 1997:81-116.
55. Stavro GM, Ettenhofer ML, Nigg JL. Executive functions and adaptive functioning in young adult attention-deficit/hyperactivity disorder. J Int Neurol Soc 2007;13:324-334. (Pubitemid 46487362)
56. Faraone SV, Biederman J, Spencer TJ, et al. Diagnosing adult attention deficit hyperactivity disorder: are late onset and subthreshold diagnoses valid? Am J Psychiatry 2006;163:1720-1729. (Pubitemid 44522480)
57. Shibao C, Raj SR, Gamboa A, et al. Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension 2007;50:47-53. (Pubitemid 46986009)
58. Virani AS, Bezchulibnyk-Butler KZ, Jeffries JJ. Clinical Handbook of Psychotropic Drugs. 18th ed. Gottingen, Germany: Hogrefe & Huber, 2009:224.